Mechanisms of drug resistance in cancer therapy. (2019)

• Record Type: Book
• Further Information: Note: Mario Mandalà, Emanuela Romano, editors.
• Editors: Mandalà, Mario; Romano, Emanuela
• Contents: Intro; Preface; Contents; Molecular and Pharmacological Mechanisms of Drug Resistance:An Evolving Paradigm; 1 Introduction; 2 Cellular Mechanism of Multidrug Resistance; 2.1 Drug Activation and Inactivation; 2.2 Expression of Drug Efflux Pumps; 2.3 DNA Damage Repair; 2.4 Deregulation of Apoptosis; 2.5 Alteration of Drug Target; 3 Conclusion; References; Major Physiological Signaling Pathways in the Regulation of Cell Proliferation and Survival; 1 Introduction; 2 Signaling Pathways Involved in the Regulation of Cell Proliferation 2.1 Biological Regulation of Proliferation by mTOR/PI3K/Akt Signaling2.2 Ras/MAPK Signaling-Regulated Cell Proliferation, Differentiation, and Survival; 2.3 JAK/STAT Signaling in the Regulation of Cell Proliferation and Survival; 3 Signaling Interaction Network Between PI3K/Akt, Ras/MAPK, and JAK/STAT Axes; 4 Output Signals of Integrated Signaling Pathways; 4.1 Redundant Targeting of Shared Substrates in Cell Growth and Metabolism; 4.2 Differential Phospho-Regulation of Shared Substrates in Cell Proliferation and Survival; 5 Impact of Signaling Interaction Network in Clinical Cancer Therapies 6 Final RemarksReferences; Immune-Mediated and Hypoxia-Regulated Programs: Accomplices in Resistance to Anti-angiogenic Therapies; 1 Introduction; 2 Mechanisms of Resistance to Anti-angiogenic Therapies; 2.1 Expression of Alternative Pro-angiogenic Mediators; 2.2 Adaptation to Hypoxia; 3 Immune-Mediated Mechanisms of Resistance to Anti-angiogenesis; 3.1 Myeloid Cell-Dependent Resistance to Anti-angiogenic Therapies; 3.1.1 Pericytes; 3.1.2 CD11b+Gr1+ MDSCs; 3.1.3 Macrophages; 3.1.4 Dendritic Cells; 3.1.5 Mast Cells; 3.2 Lymphoid Cell-Dependent Resistance to Anti-angiogenic Therapies 4 Hypoxia Bridges Immune Tolerance and Angiogenesis in TME5 The Galectin-Glycan Axis: Linking Immunosuppression, Hypoxia, and Resistance to Anti-angiogenic Treatment; 5.1 Galectins as Extracellular Mediators of Angiogenesis; 5.2 Galectins as Mechanisms of Resistance to VEGF Blockade; 5.3 Targeting Gal1-N-Glycan Interactions Limits the Efficacy of Anti-VEGF Treatment; 6 Combinatorial Therapies: Anti-angiogenesis as a Partner of Immunotherapy; 7 Conclusions and Future Perspectives; References; Mechanisms of Resistance to Target Therapies in Non-small Cell Lung Cancer; 1 Introduction 2 Resistance Mechanisms to EGFR-Driven NSCLC2.1 Resistance to First- and Second-Generation EGFR-TKIs; 2.1.1 Preclinical Evidence and Clinical Relevance of Resistance Mechanisms; 2.1.2 Detection of T790M Mutation; 2.1.3 Potential Strategies to Overcome Resistance; 2.2 Resistance to Third-Generation EGFR-TKIs; 2.2.1 Preclinical Evidence and Clinical Relevance of Resistance Mechanisms; 2.2.2 Potential Strategies to Overcome Resistance; 3 Resistance Mechanisms to ALK- and ROS1-Driven NSCLC; 3.1 Mechanisms of Crizotinib Resistance; 3.1.1 Mechanisms of Crizotinib Resistance Involving ALK and ROS1
• Publisher Details: Cham : Springer
• Publication Date: 2019
• Copyright Date: 2018
• Extent: 1 online resource (297 pages)
• Subjects: 616.99/4061; Drug resistance in cancer cells; Cancer -- Chemotherapy; Drug Resistance; Neoplasms -- drug therapy; Cancer -- Chemotherapy; Drug resistance in cancer cells
• Languages: English
• ISBNs: 9783030105075
• Related ISBNs: 9783030105068
• Access Rights: Legal Deposit; Only available on premises controlled by the deposit library and to one user at any one time; The Legal Deposit Libraries (Non-Print Works) Regulations (UK).
• Access Usage: Restricted: Printing from this resource is governed by The Legal Deposit Libraries (Non-Print Works) Regulations (UK) and UK copyright law currently in force.